Renovaro seeks strategic investors for up to 20% of subsidiary Cube

Lunai Bioworks Inc.

Board intends to offer up to 20% ownership in RenovaroCube, a wholly owned molecular data science subsidiary.
Cube uses proprietary AI for multi-omics analysis to accelerate precision medicine, starting with cancer.
Proceeds from the offering expected to advance Cube's platform and go-to-market strategy.
Subscription terms to be determined as investors are identified and approved by Renovaro's Board.
RenovaroBio continues work on patented cancer vaccine targeting pancreatic, head and neck, liver tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.